The Clinical and pathological characteristics and survival of patients with advanced ovarian cancer

Miroslav Popovic; Tanja Milić Radić; Arnela Cerić Banićević

doi:10.5937/scriptamed52-33897

Miroslav Popovic Univerzitet u Banjoj Luci, Medicinski fakultet, Univerzitetski Klinički centar, Klinika za Ginekologiju i akušerstvo.
Tanja Milić Radić University Clinical center of Republika Srpska
Arnela Cerić Banićević University Clinical center of Republika Srpska

DOI: https://doi.org/10.5937/scriptamed52-33897

Keywords: Ovarian cancer, Radical operation, Survival

Abstract

Introduction: Ovarian cancer has the highest mortality rate of all gynaecologic malignancies. The aim of this study was the evaluation of the clinical patholog- ical characteristics and survival analysis of primarily operated patients with advanced stages of malignant epithelial ovarian tumour.

Methods: The research was conducted as a cohort study with 59 patients with FIGO stage III and IV, which were primarily operated between 1 January 2008 and 31 December 2010 (three years). Age, comorbidities, BMI, presence of asci- tes, the level of the marker CA-125, histopathology and FIGO stage were anal- ysed. The survival rate was estimated at the level of 1, 3 and 5 years.

Results: The median age was 53 years (range 29-86). The most common histo- pathological type was serous (66.1 %) and the most common FIGO stage was 3a (49.2 %). Optimal cytoreduction was performed in 35.5 % of patients, 84.7 % of patients survived for one year, 44.1 % three years and 37.3 % for five years. The median survival was 26.25 months (range 0-91). Chi-square test showed signif- icant difference between the number of months of survival and: the value of CA- 125 (t = 2.004, p = 0.050), cytoreduction (p < 0.001) and FIGO stage (p < 0.01).

Conclusion: According to the results of this study, optimal cytoreduction and FIGO stage significantly influence survival (p < 0.001). Optimal cytoreduction (< 2 cm of residual disease) had the highest prognostic value for survival. A total five-year survival in this study was 37.3 %.

Author Biography

Miroslav Popovic, Univerzitet u Banjoj Luci, Medicinski fakultet, Univerzitetski Klinički centar, Klinika za Ginekologiju i akušerstvo.

Osnovni biografski podaci

Ime i prezime: Miroslav D. Popović

Datum i mjesto rođenja: 07. 2. 1974 .godine u Banjaluci, BiH

Ustanova gdje je zaposlen: Klinika za ginekologiju i akušerstvo KC Banja Luka od 2010. god , ljekar specijalista, subspecijalista.

Naučna oblast: Ginekologija i akušerstvo

Stručna biografija, diplome i zvanja

Medicinski fakultet Banjaluka: 1993-1999. godine

Specijalistički ispit: Ginekologija i akušerstvo: 2004.godine. Medicinski fakultet Banja Luka

Postdiplomski studij “Biomedicinska istraživanja“Medicinski fakultet Banjaluka 2007. Godine, prosječna ocjena 9,5

Magistarski rad: Medicinski fakultet Univerziteta u Banjaluci 2012.godine, mentor: Prof. dr Vesna Ećim-Zlojutro, Naslov magistarskog rada: “UTICAJ INTRAUTERINOG ZASTOJA U RASTU PLODA NA ISHOD TRUDNOĆE “

Subspecijalizacija: ONKOLOGIJA Medicinski fakultet Beograd , 2012-2013. godine , Subpecijalistički ispit: Ocjena 9, 2013. godine.

Subpecijalistički rad Medicinski fakultet Beograd , 2013 g, mentor: Prof. dr Vladimir Pažin, Naslov subspecijalističkog rada: “KORELACIJA PREOPERATIVNOG I POSTOPERATIVNOG PATOHISTOLOŠKOG NALAZA KOD BOLESNICA SA KARCINOMOM ENDOMETRIJA”

Naučni i Stručni rad:

Do sad publikovao 20 stručnih radova i dvije knjige. Uveo u ginekološku praksu na KGA Banja Luka endoskopsko liječenje ginekoloških maligniteta, a 9.3.2016. god uradio prvu laparaskopsku radikalnu histerektomiju.

References

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011 Mar- Apr;61(2):69-90.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49.

Dotlic J, Terzic M, Likic I, Atanacković J, Ladjević N. Evaluation of adnexal masses: correlation of clinical stage, ul- trasound andhystopathological findings. Vojnosanit Pregl 2011;68:861-6.

Terzic M, Dotlic J, Likic I, Ladjevic N, Brndusic N, Mihai- lovic T, et al. Predictive factors of malignancy in patients with adnexal masses. Eur J Gynaec Oncol 2013;34:65-9.

Gazibara T, Filipović A, Kesić V, Kisiĉ-Tepavcević D, Pek- mezović T. Risk factors for epithelial ovarian cancer in the female population of Belgrade, Serbia: a case-control study. Vojnosanit Pregl 2013;70:1097-102.

Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol 2011;32:1087-95.

Alleti G, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gyneacol 2006,107:77-85.

Fotopoulou C, Savvatis K, Kosian P, Braicu IE, Papaniko- laou G, Pietzner K, Schmidt SC, Sehouli J. Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? Br J Cancer 2013 Jan 15;108(1):32-8.

Bachmann R, Rothmund R, Krämer B, Brucker SY, Königs- rainer A, Königsrainer I, et al. The prognostic role of optimal cytoreduction in advanced, bowel infiltrating ovari- an cancer. J Invest Surg 2015 Jun;28(3):160-6.

Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective. Acta Obstet Gynecol Scand 2012;91:308-17.

Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.

Grann AF, Nørgaard M, Blaakær J, Søgaard-Andersen E, Jacobsen JB. Survival of patients with ovarian cancer in central and northern Denmark 1998-2009. Clin Epidemiol 2011;3 (Suppl 1):59-64.

Chi DS, Eisenhauer EL, Land J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma(EOC)? Gynecol Oncol 2006;103:559–64.

Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev 2014 Feb 21;2014(2):CD009786. doi: 10.1002/14651858.CD009786.pub2.

Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol 2016 Aug;142(2):211-6.

Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol 2016 Mar;140(3):436-42.

Fotopoulou C, Jones BP, Savvatis K, Campbell J, Kyrgiou M, Farthing A, et al. Maximal effort cytoreductive sur- gery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Arch Gynecol Obstet 2016 Sep;294(3):607-14.

Brun JL, Feyler A, Chêne G, Saurel J, Brun G, Hocké C. Long- term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000 Jul;78(1):21-7.

Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS, Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol 2015 Sep;126(3):491-7.

Malkasian GD Jr, Decker DG, Webb MJ. Histology of epithe- lial tumors of the ovary: clinical usefulness and prognostic significance of the histologic classification and grading. Semin Oncol 1975 Sep;2(3):191-201.

Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994 Dec;55(3 Pt 2):S91- 6. doi: 10.1006/gyno.1994.1346.

Bookman MA. Optimal primary therapy of ovarian cancer. Ann Oncol 2016 Apr;27 Suppl 1:i58-i62. doi: 10.1093/annonc/mdw088.

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858. CD007565.pub2.

Ørskov M, Iachina M, Guldberg R, Mogensen O, Mertz Nørgård B. Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study. BMJ Open 2016 Apr 21;6(4):e010123. doi: 10.1136/bmjop- en-2015-010123.